If you or someone you love has experienced a spinal cord injury, the question of walking again sits at the center of almost every conversation. The ReWalk exoskeleton is not a promise or a prototype. It is an FDA-cleared, wearable robotic suit that lets people with certain spinal cord injuries stand up, walk forward, turn, and in the newest version, climb stairs. This guide walks through everything a real patient or family member needs to know, from how the device works to what it costs after Medicare kicks in, who qualifies, and what daily life actually looks like once training is complete.
At a Glance
| Topic | Key Facts |
|---|---|
| Device type | Wearable powered exoskeleton for lower limb paralysis |
| Manufacturer | Lifeward (formerly ReWalk Robotics), founded in Israel |
| FDA clearance | Personal use: 2014; Stair/curb capability: 2023; ReWalk 7: March 2025 |
| Primary indication | Spinal cord injury at T7 to L5 (personal use) |
| Medicare coverage | Established April 2024; CMS lump-sum rate of $91,032 |
| VA coverage | Available since December 2015, zero out-of-pocket for eligible veterans |
| Battery life | Up to 8 hours (longest in its class) |
| Certified training sites | 142 VA and private centers across the United States |
What Is the ReWalk Exoskeleton?
The ReWalk exoskeleton is a motorized, wearable frame worn over the lower body that enables people with paraplegia to stand upright and walk. It was developed by Dr. Amit Goffer, an Israeli engineer who was himself paralyzed, and is now manufactured and distributed by Lifeward, the company formerly known as ReWalk Robotics. The device received FDA clearance for personal home use in 2014, making it the first powered exoskeleton to earn that designation in the United States. In 2023, FDA clearance was expanded to include stair and curb navigation on the ReWalk Personal 6.0. The newest generation, the ReWalk 7, received FDA clearance in March 2025 and began its U.S. launch in April 2025.
ReWalk is not a cure for spinal cord injury, and the company does not position it as one. It is a mobility device that works alongside ongoing rehabilitation and, in most cases, alongside a wheelchair. Think of it the way a hearing aid works alongside other communication tools: it restores a specific function in a specific context and builds from there.
How Does It Work Mechanically?
The ReWalk exoskeleton uses battery-powered motors at both the hip and knee joints to drive a walking gait. A body-tilt sensor worn on the torso detects when the user leans forward, which triggers the system to initiate a step. The user then controls the pace and direction using a wrist-mounted control unit, a feature that was significantly redesigned in the ReWalk 7. Two selectable walking speeds allow the user to adapt to different environments. The battery supports up to 8 hours of use per charge, which is the longest runtime of any FDA-cleared personal exoskeleton currently available. Forearm crutches are required for balance and upper-body support throughout use, which means adequate arm and shoulder strength is a prerequisite for candidacy.
ReWalk 7 vs ReWalk Personal 6.0
The ReWalk Personal 6.0 and its stair-capable update represent the previous generation; the ReWalk 7, launched in April 2025, introduces several meaningful upgrades. Stair and curb navigation, which required a separate FDA clearance for the 6.0 in 2023, is now standard in the ReWalk 7 out of the box. The 7 also adds cloud connectivity, a companion smartwatch paired with the MyReWalk app for monitoring and session logging, and a dedicated handheld device for physical therapists that allows real-time parameter adjustments during training sessions. Walking speed options are wider in the ReWalk 7, with two configurable speeds. The control interface itself has been redesigned for more intuitive use.
Patients currently in the clinical pipeline may encounter the 6.0 in a training center setting, particularly at VA facilities still in transition. For new personal-use purchases initiated from mid-2025 onward, the ReWalk 7 is the device patients will be evaluated for.
Who Qualifies for a ReWalk Exoskeleton?
This section answers the question most competing resources leave unanswered. FDA clearance defines the baseline, but individual clinical assessment determines actual candidacy. Qualifying is not simply about having a spinal cord injury.
For personal home use, the FDA-cleared indication covers spinal cord injuries at levels T7 through L5. In supervised rehabilitation settings, the cleared range extends higher, to T4 through T6. Both complete and incomplete spinal cord injuries may qualify, provided the physical prerequisites are met.
Physical criteria include sufficient upper-body and arm strength to control forearm crutches throughout the session, since the device does not replace the need for crutch support. Height and weight parameters apply, as the device is engineered for a specific frame range; Lifeward's clinical team screens for this during the evaluation process. Adequate bone density is required to tolerate the mechanical loads of upright walking, and skin integrity must be intact, particularly over bony prominences. Spasticity level is also assessed, with moderate-to-severe uncontrolled spasticity typically being a contraindication.
Conditions the ReWalk Supports
The primary indication is traumatic and non-traumatic spinal cord injury. Lifeward has ongoing research into expanded conditions, but as of 2025, the FDA-cleared personal-use indication in the United States applies specifically to SCI within the T7 to L5 range. A physiatrist or SCI specialist can clarify whether an individual's ASIA classification and injury level fall within the cleared range.
Who May Not Be a Candidate
Some conditions make ReWalk use inappropriate or unsafe. Severe osteoporosis or fragile bone conditions raise the risk of fracture under the loads of powered ambulation. Severe uncontrolled spasticity can interfere with the triggered gait pattern. Anyone unable to bear weight through the upper extremities with crutches, due to shoulder injury, severe weakness, or another upper limb condition, would not meet the physical prerequisites. Active pressure wounds or open skin lesions, particularly over areas that contact the device frame, are a contraindication until resolved. Significant cardiovascular or respiratory instability may also preclude training.
Being transparent about contraindications saves patients time and protects them from pursuing an evaluation that will not lead to clearance.
What Are the Proven Health Benefits?
The clinical case for the ReWalk exoskeleton goes beyond restoring the ability to walk. Research points to measurable improvements across multiple body systems, and the quality-of-life findings are among the most compelling in the literature.
Physical Health Outcomes
Upright weight-bearing in the ReWalk has been associated with improved bone mineral density at sites that typically deteriorate rapidly after spinal cord injury. Spasticity reduction has been reported in several trials, likely related to the rhythmic, patterned movement the device produces. Bowel and bladder function improvements have been documented in users who completed extended training programs, which may relate to the postural and movement changes that accompany regular upright ambulation. Cardiovascular conditioning improves with sustained use, since walking with the device produces a metabolic demand comparable to moderate-intensity walking in able-bodied individuals. Trunk control and core activation also develop over the course of a structured training program.
Mental Health and Quality of Life
This is the dimension most product pages and encyclopedia entries skip entirely, but it is often the reason patients pursue the device in the first place.
The ability to stand at eye level during social interactions is consistently reported by ReWalk users as one of the most emotionally significant changes. Looking someone in the face rather than up at them shifts relational dynamics in ways that go beyond physical function. Community participation, including the ability to navigate environments that are inaccessible by wheelchair, expands the radius of daily life. For many users, the device represents a return to a version of independence they believed was permanently lost.
ReWalk vs Ekso Indego: How the Two FDA-Approved Personal Exoskeletons Compare
Two powered exoskeletons currently hold FDA clearance for personal home use in the United States: the ReWalk Personal and the Ekso Indego Personal. Both are excellent devices, and the right choice depends on the individual's injury level, body, goals, and clinical context.
| Feature | ReWalk 7 | Ekso Indego Personal |
|---|---|---|
| SCI level (personal use) | T7 to L5 | T3 to L5 |
| Stair/curb capability | Yes (standard) | No |
| Battery life | Up to 8 hours | Approximately 4 hours |
| Max walking speed studied | 0.71 m/s | Varies by configuration |
| Medicare coverage | Yes (since April 2024) | Yes (since April 2024) |
| Cloud connectivity | Yes (ReWalk 7) | No |
| Therapist control interface | Yes (ReWalk 7 handheld device) | Limited |
The Ekso Indego covers a wider injury-level range on the upper end, reaching T3, which makes it the only option for some patients with higher thoracic injuries seeking personal-use clearance. The ReWalk 7 leads on battery life, stair capability, and digital connectivity. Both are billed under Medicare's brace benefit category and became Medicare-covered in the same April 2024 policy update. A physiatrist familiar with both devices is the right person to guide the comparison for any individual patient.
How to Get Coverage: Insurance and Cost in 2026
This is the section most patients search for and most published pages leave incomplete. Coverage has changed substantially since 2024, and the landscape continues to shift. The information below reflects the situation as of early 2026.
Medicare
Medicare coverage for personal exoskeletons was established in April 2024, when the Centers for Medicare and Medicaid Services set a lump-sum payment rate of $91,032 for the ReWalk Personal under the Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) brace benefit category. Under standard Medicare Part B, the beneficiary is responsible for a 20% copay after the deductible, which works out to approximately $18,200. A secondary insurance policy or Medigap plan can cover that copay in many cases, bringing the out-of-pocket cost down significantly or to zero for some beneficiaries.
A key development in mid-2025 was an Administrative Law Judge (ALJ) ruling that reinforced the "reasonable and necessary" standard for exoskeleton coverage, providing additional legal grounding for prior authorization approvals. Prior authorization is required. The general pathway involves a physician order from a physiatrist or SCI specialist, documentation of the qualifying diagnosis and physical assessment, and submission through a Medicare-enrolled DMEPOS supplier.
If you are navigating this process, consulting with a qualified specialist is the right starting point. You can find a physiatrist or spinal cord injury specialist through a physician directory to begin the evaluation and documentation process.
Medicare Advantage
Medicare Advantage plans have been slower to follow traditional Medicare, but coverage is expanding rapidly. UnitedHealthcare issued prior authorization approvals for the ReWalk Personal in November 2025. Humana followed in December 2025. Aetna issued approvals in February 2026. As of early 2026, nearly half of all Medicare Advantage enrollees are now enrolled in plans that cover the device. Coverage is not automatic under Medicare Advantage. Each plan requires individual prior authorization, and the criteria may differ slightly from plan to plan. Lifeward's reimbursement team maintains current information on which plans are approving claims and can assist with the submission process.
VA Coverage
The VA has covered the ReWalk exoskeleton since December 2015, making it one of the longest-running coverage pathways available. Coverage extends to any veteran with a spinal cord injury, whether service-related or not. The VA pathway involves evaluation at one of 24 designated SCI centers across the country, with training conducted at any of 142 ReWalk-certified centers. Eligible veterans pay nothing out of pocket. The process begins with a referral from a VA primary care physician to the nearest SCI center, followed by a clinical evaluation, a training program, and then device procurement through the VA supply chain. The VA pathway is generally the most straightforward route for eligible veterans.
Commercial and Workers' Compensation Insurance
Commercial insurer coverage remains in earlier stages, though the first major commercial insurer approval came in 2025. Workers' compensation coverage is handled case by case, and documented precedent exists for successful approvals. Lifeward's reimbursement team works directly with policyholders and attorneys to support prior authorization submissions in both commercial and workers' comp contexts. The team can be reached through Lifeward's official website at golifeward.com.
Out-of-Pocket Cost Reality
Without insurance, the list price for a ReWalk personal exoskeleton ranges from approximately $85,000 to $109,000 depending on configuration. After Medicare coverage with no secondary insurance, the out-of-pocket cost is approximately $18,200. For context, the lifetime additional healthcare costs associated with a high-level spinal cord injury can exceed $1 million over a 40-year period, according to data from the National Spinal Cord Injury Statistical Center. Lifeward's reimbursement team actively assists with coverage navigation and, in some cases, financial assistance programs.
What Does the Training Process Look Like?
No ranking result for the ReWalk exoskeleton answers this question, which is one of the most practical things a prospective user needs to understand before committing to the process.
Training typically takes place three times per week, with each session lasting between 60 and 120 minutes depending on the user's current level and the phase of training. The full program can range from 1 to 24 weeks, based on the individual's prior rehabilitation history, injury level, and how quickly they progress through the milestones. A certified physical therapist is required for all training sessions. The therapist uses the ReWalk 7's dedicated handheld device to adjust parameters in real time, including step cadence and sensitivity thresholds, as the user progresses.
Donning the device initially takes 10 to 20 minutes, though most users reduce that time significantly with practice. A companion or caregiver is trained alongside the primary user, both to assist with donning and to provide safety support during community use. "Passing" training means demonstrating the ability to initiate walking, stop safely, change direction, manage the control interface independently, and in the ReWalk 7, navigate stairs and curbs under controlled conditions.
Finding a Certified Training Center
There are 142 VA and private certified ReWalk training centers across the United States. To locate one, Lifeward's website provides a center locator tool. When contacting a center, useful questions to ask include: whether the center has experience with the ReWalk 7 specifically, how many patients the therapists have trained through to independent use, and what the typical wait time is for an initial evaluation. VA SCI centers listed on the VA's website handle both evaluation and training for eligible veterans.
What Is Life Like With a ReWalk Exoskeleton?
The clinical picture tells part of the story. The rest comes from the documented lived experiences of people who use the device regularly.
Most users describe ReWalk as a complement to their wheelchair, not a replacement for it. The device is used for structured walking sessions, community outings, and specific environments where upright mobility offers a social or functional advantage. With the ReWalk 7's stair and curb capability, more environments become navigable, including buildings with stairs, outdoor terrain, and situations where a wheelchair would require assistance.
Daily routine integration typically involves a dedicated time for donning and a planned session, rather than constant use throughout the day. Users report that the planning required becomes second nature over time. The eye-level social interaction that standing enables comes up repeatedly in published user accounts. Conversations, retail interactions, and social gatherings feel different when conducted at standing height, and that shift carries psychological weight that clinical studies have begun to quantify.
Peer support networks exist within the ReWalk user community, facilitated in part through Lifeward's patient programs. Connecting with other users before and during training has been associated with better adherence and higher satisfaction in rehabilitation literature.
How to Take the Next Step
The path forward depends on your situation, but it follows one of three clear routes.
For most patients, the starting point is a conversation with a physiatrist or spinal cord injury specialist. Bring the candidacy criteria listed above to that appointment. Questions to cover include injury level and ASIA classification, bone density status, upper extremity strength, current spasticity levels, and whether any active skin issues would need to resolve before evaluation. A physiatrist can advise on individual cases and initiate the documentation needed for insurance submission.
For veterans, the starting point is a referral from a VA primary care physician to the nearest VA SCI center. The evaluation, training, and device procurement process is handled within the VA system at no cost.
For everyone, Lifeward's reimbursement team is a parallel resource. They can identify which DMEPOS suppliers in your area are Medicare-enrolled for the ReWalk, advise on the status of your specific Medicare Advantage plan, and assist with prior authorization documentation for commercial or workers' compensation coverage.
Pre-appointment checklist: confirm your injury level and ASIA classification from your records, note your current height and weight, bring a list of current medications and any comorbidities, and identify whether you have a companion or caregiver who could participate in training.
For broader guidance on navigating your health information and care options, the Momentary Lab AI Healthcare Navigator can help you orient your next steps and find relevant resources.
Frequently Asked Questions
How much does the ReWalk exoskeleton cost?
The list price for a ReWalk personal exoskeleton ranges from approximately $85,000 to $109,000 depending on the model and configuration. After Medicare coverage, beneficiaries are responsible for a 20% copay of the $91,032 CMS reimbursement rate, which works out to approximately $18,200. A secondary insurance policy or Medigap plan may cover that copay. Veterans eligible for VA coverage pay nothing out of pocket.
Does Medicare cover the ReWalk exoskeleton?
Yes. Medicare began covering the ReWalk Personal exoskeleton in April 2024 under the DMEPOS brace benefit category. The CMS lump-sum payment rate is $91,032. Coverage requires prior authorization, a qualifying diagnosis, and a physician order from a physiatrist or SCI specialist. An ALJ ruling in mid-2025 further reinforced the coverage standard.
How does the ReWalk exoskeleton work?
The ReWalk uses battery-powered motors at the hip and knee joints to produce a walking gait. A body-tilt sensor on the torso detects forward lean and triggers the step sequence. The user controls pace and direction through a wrist-mounted unit. Forearm crutches are used for balance. The battery supports up to 8 hours of use per charge.
Who qualifies to use a ReWalk exoskeleton?
FDA clearance for personal home use covers spinal cord injuries at the T7 to L5 level. Physical prerequisites include sufficient upper-body strength for crutch use, appropriate height and weight, adequate bone density, intact skin, and low-to-moderate spasticity. A physiatrist conducts the formal candidacy evaluation. Both complete and incomplete spinal cord injuries may qualify.
What is the difference between the ReWalk 7 and the ReWalk Personal 6.0?
The ReWalk 7, launched in April 2025, adds stair and curb navigation as a standard feature, cloud connectivity, a smartwatch paired with the MyReWalk app, a therapist handheld device for real-time parameter adjustment, and wider walking speed options. The ReWalk Personal 6.0 received stair/curb capability as an add-on via a 2023 FDA clearance update. Most new personal-use purchases from mid-2025 onward will involve the ReWalk 7.
Is the ReWalk covered by the VA?
Yes. The VA has covered the ReWalk exoskeleton since December 2015 for veterans with spinal cord injury, regardless of whether the injury is service-related. The process begins with a VA PCP referral to a VA SCI center, followed by evaluation, training, and device procurement. There is no out-of-pocket cost for eligible veterans.
